scholarly journals Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

2015 ◽  
Vol 373 (26) ◽  
pp. 2499-2511 ◽  
Author(s):  
Michael Schaapveld ◽  
Berthe M.P. Aleman ◽  
Anna M. van Eggermond ◽  
Cécile P.M. Janus ◽  
Augustinus D.G. Krol ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Second Cancer ◽  
Second Cancer Risk

Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study

2011 ◽  
Vol 29 (31) ◽  
pp. 4096-4104 ◽  
Author(s):  
Anthony J. Swerdlow ◽  
Craig D. Higgins ◽  
Paul Smith ◽  
David Cunningham ◽  
Barry W. Hancock ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Second Primary ◽  
Second Cancer ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Second Cancer Risk

Purpose We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any yet published, to our knowledge. Patients and Methods We followed 5,798 patients with HL treated with chemotherapy in Britain from 1963 to 2001—of whom 3,432 also received radiotherapy—to assess second primary malignancy risks compared with general population-based expectations. Results Second malignancies occurred in 459 cohort members. Relative risk (RR) of second cancer was raised after chemotherapy alone (RR, 2.0; 95% CI, 1.7 to 2.4) but was much lower than after combined modalities (RR, 3.9; 95% CI, 3.5 to 4.4). After chemotherapy alone, there were significantly raised risks of lung cancer, non-HL, and leukemia, each contributing approximately equal absolute excess risk. After combined modalities, there were raised risks of these and several other cancers. Second cancer risk peaked 5 to 9 years after chemotherapy alone, but it remained raised for 25 years and longer after combined modalities. Risk was raised after each common chemotherapy regimen except, based on limited numbers and follow-up, adriamycin, bleomycin, vinblastine, and dacarbazine. The age and time-course relations of lung cancer differed between chemotherapy alone and combined modalities. Conclusion Although chemotherapy alone leads to raised risk of second malignancy, this risk is lower and affects fewer anatomic sites than that after combined modalities, and it is slight if at all after 15 years follow-up. The mechanism of lung cancer etiology may differ between chemotherapy and radiotherapy.

Estimation of second cancer risk after splenic irradiation for Hodgkin’s lymphoma

2014 ◽  
Vol 30 ◽  
pp. e87-e88
Author(s):  
K. Kourinou ◽  
M. Mazonakis ◽  
A. Fasoulaki ◽  
J. Damilakis
Keyword(s):  
Cancer Risk ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Second Cancer ◽  
Splenic Irradiation ◽  
Second Cancer Risk

Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy (IMRT)

2014 ◽  
Vol 62 (2) ◽  
pp. 311-316 ◽  
Author(s):  
Dana L. Casey ◽  
Danielle N. Friedman ◽  
Chaya S. Moskowitz ◽  
Patrick D. Hilden ◽  
Charles A. Sklar ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cancer Risk ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Intensity Modulated Radiation Therapy ◽  
Childhood Cancer Survivors ◽  
Second Cancer ◽  
Intensity Modulated ◽  
Second Cancer Risk

Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer

2014 ◽  
Vol 110 (3) ◽  
pp. 471-476 ◽  
Author(s):  
Yasser Abo-Madyan ◽  
Muhammad Hammad Aziz ◽  
Moamen M.O.M. Aly ◽  
Frank Schneider ◽  
Elena Sperk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Second Cancer ◽  
Second Cancer Risk ◽  
3D Crt
Sign in / Sign up

Export Citation Format

Share Document